Low Doses of Heparin in Prevention of Deep-Vein Thrombosis

“…It is well known that standard heparin used in a defined manner [4,5,7,9,11,12,14. 15] does not efficiently prevent DVT in elective hip surgery (table X).…”

Section: Discussionmentioning

confidence: 99%

Enoxaparine Low Molecular Weight Heparin: Its Use in the Prevention of Deep Venous Thrombosis Following Total Hip Replacement

Planès¹,

Vochelle²,

Ferru³

et al. 1986

“…Several studies [5,6,9,11,14,25] have now confirmed that a standard regimen of low-dose heparin is quite effective in preventing DVT in patients undergoing a variety of general abdominal operations. However, the results have been less encouraging in patients undergoing total hip replacement; in a study reported by K a k k a r et al [11], 4 (27%) of 15 such patients devel oped thrombosis.…”

Section: Discussionmentioning

confidence: 97%

“…Several recent trials [2,5,6,9,11,12,14,25] have demonstrated that low-dose heparin prophylaxis significantly reduces the incidence of deep vein thrombosis (DVT) detected by the 125I-fibrinogen test. In other controlled trials, heparin prophylaxis has been shown to be more effective than oral anticoagulants [23] or pre-and postoperative infusion of Dextran 70 [24],…”

Section: Introductionmentioning

confidence: 99%

Controlled Trial of Platelet Anti-Aggregating Agents and Subcutaneous Heparin in Prevention of Postoperative Deep Vein Thrombosis in High Risk Patients

Dechavanne¹,

Ville²,

Viala³

et al. 1975

In a prospective randomised trial, three groups of 20 patients each were compared. A first group served as a control, a second group received dipyridamole and acetylsalicylic acid and a third group received low doses of heparin. The incidence of deep vein thrombosis determined by the ¹²⁵I-fibrinogen test was 40 % in the first group, 50 % in the second group, and 5 % in the third group. The differences between the heparin group and the two other groups are statistically significant. No wound complication and no haematoma at the injection site occurred.

“…It may therefore be argued that prevention of DVT requires widespread adoption of effec tive pharmacological methods. Subcutaneous low doses of heparin reduce the incidence of postoperative DVT, as detected by l25I-la-belled fibrinogen, but this treatment can be accompanied by an increased risk of hemor rhagic complications [6,7], These observa tions prompted us to investigate the effec tiveness of a new antithrombotic compound, defibrotide, a polydeoxyribonucleotide ex tracted from mammalian organs [8,9] for prophylaxis of postoperative DVT in a dou ble-blind, randomized clinical trial in pa tients undergoing gynecological surgery.…”

Section: Introductionmentioning

confidence: 99%

Effectiveness of Defibrotide for Prophylaxis of Deep Venous Thrombosis in Gynecological Surgery: A Double-Blind, Placebo-Controlled Clinical Trial

Ciavarella

Ettorre

Schiavoni

et al. 1986

Defibrotide, a new antithrombotic compound without anticoagulant activity, has been tested for prevention of deep venous thrombosis (DVT) in patients undergoing gynecological surgery (mainly hysterectomy). Eighty-nine women (mean age 48.5) were randomly allocated to defibrotide (44 patients) or placebo (45 patients). 800 mg defibrotide was given daily (200 mg intravenously 4 times a day), starting on the day before operation and then for the next 7 days. DVT were detected by the conventional ¹²⁵I-fibrinogen test. The two groups were homogeneous for known risk factors (age, varicosities, obesity, neoplasia and previous thromboembolic episodes). The results showed a statistically significant reduction of DVT incidence in patients on defibrotide, as compared with those on placebo: 4/44 = 9% vs. 13/45 = 28.8% (p < 0.05). There were no side effects, including hemorrhagic complications. The numbers of units transfused were comparable for the 2 groups. In conclusion, the trial shows that defibrotide is an effective and safe drug for the prevention of DVT in gynecological surgery.